The article reports on the issues behind the GlaxoSmithKline's decision to pull its vaccine, LYMErix from the market. The initial approval of its release to the market by the vaccine advisory committee of U.S. Food and Drug Administration (FDA) was hedged with caveats regarding its safety and usefulness.